EMA Authorised: Docetaxel Kabi (docetaxel) — Fresenius Kabi Deutschland GmbH

View source ↗

Summary

EU authorization of Docetaxel Kabi (docetaxel) for multiple cancer indications including head and neck neoplasms, non-small cell lung carcinoma, adenocarcinoma,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma
• Breast Neoplasms
• Carcinoma Non-small-cell Lung
• Head and Neck Neoplasms
• Prostatic Neoplasms

Drugs mentioned

• Docetaxel Kabi (docetaxel)

Snippet

Status: Authorised. Therapeutic area: Head and Neck Neoplasms;Carcinoma, Non-Small-Cell Lung;Adenocarcinoma;Prostatic Neoplasms;Breast Neoplasms. MAH: Fresenius Kabi Deutschland GmbH. Decision date: 04/08/2025